Approximately 3 decades ago, the standard of care for patients with heart failure with
reduced ejection fraction was digoxin and diuretics. 1 The path to defining guideline …

Heart failure (HF) is a leading cause of mortality, morbidity, and hospitalization in older
adults. 1 The combination of four classes of guideline-directed medical therapies (GDMTs) …

Heart failure is a leading cause of morbidity and mortality globally. The natural history of
heart failure with reduced ejection fraction (HFrEF) has been altered with the development of …

A few decades ago, the biggest challenge with the treatment of heart failure with reduced
ejection fraction (HFrEF) was the paucity of effective drug therapy that substantially improved …

The treatment of heart failure (HF) with reduced ejection fraction (HFrEF) has substantially
developed over the past decades. More than ever before, the application of appropriate …

Guidelines are written for clinicians. The uneven uptake of recommendations to date may
reflect ambivalence in the clinician's perception of the status of 'guidance', a vulnerability to …

Real-world dosing of evidence-based medications for heart failure: embracing guideline
recommendations and clinical judgement. - Abstract - Europe PMC Sign in | Create an account …

High-quality, evidence-based policies represent an important medium for promoting and
improving cardiovascular health worldwide. Cardiovascular disease is among the highest …

Recent advances in pharmacotherapy for heart failure with reduced ejection fraction (HFrEF)
have now afforded multiple, highly efficacious, life-prolonging treatments for this highrisk …

Introduction 1–2% of the population in the industrialized parts of the world in which at least 1
billion out of the world's 6 billion people live suffer from heart failure. The prevalence of …